Ozenoxacin

Ozenoxacin
Clinical data
Pronunciationoz en ox' a sin
Trade namesOzanex; Xepi
AHFS/Drugs.comMonograph
MedlinePlusa618010
License data
Routes of
administration		Topical
ATC code
Legal status
Legal status
Identifiers
  • 1-Cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H21N3O3
Molar mass363.417 g·mol−1
3D model (JSmol)
  • O=C\3c1c(c(c(cc1)c2cc(c(nc2)NC)C)C)N(/C=C/3C(=O)O)C4CC4
  • InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
  • Key:XPIJWUTXQAGSLK-UHFFFAOYSA-N

Ozenoxacin, sold under the brand names Ozanex and Xepi, is a quinolone antibiotic used for the treatment of impetigo.[4] A 1% topical cream is approved for treatment of impetigo in Canada[5] and in the United States.[6][7]

Ozenoxacin is active against some bacteria that have developed resistance to fluoroquinolone antibiotics.[8]

  1. ^ "Skin health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
  2. ^ "Xepi- ozenoxacin cream". DailyMed. 30 January 2020. Retrieved 13 October 2020.
  3. ^ "List of nationally authorised medicinal products" (PDF). Retrieved 2024-05-20.
  4. ^ "Ozenoxacin". PubChem. U.S. National Library of Medicine. Retrieved 2019-01-10.
  5. ^ "Cipher Pharmaceuticals Receives Health Canada Approval of Ozanex (ozenoxacin cream 1%)" (Press release). Cipher Pharmaceuticals Inc.
  6. ^ "Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo" (Press release). Medimetriks Pharmaceuticals, Inc. – via PRNewswire.
  7. ^ "Xepi (ozenoxacin) Cream". U.S. Food and Drug Administration (FDA). 18 January 2018. Retrieved 13 October 2020.
  8. ^ López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J (December 2013). "In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria". Antimicrobial Agents and Chemotherapy. 57 (12): 6389–6392. doi:10.1128/AAC.01509-13. PMC 3837899. PMID 24080666.